News

Company   ImmuPharma PLC
TIDM         IMM
Headline    Board Changes
Released    07:00 15-Feb-07
Number     2881R

FOR IMMEDIATE RELEASE

London, 15 February 2007

Appointment of adviser

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce the appointment of Teather & Greenwood Limited as nominated adviser and broker. The appointment is with immediate effect.

Dawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc as joint financial adviser.

For further information please contact:

ImmuPharma PLC

Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Richard Warr, Chairman                                                +44 20 7152 4080
 

Buchanan Communications                                     + 44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Notes to Editors:

About ImmuPharma

ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by:

  • blockbuster potential in niche markets

  • low promotional costs in few specialised physicians and centres and

  • lower risk of drug development and lower development costs

ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections.

END